Carvedilol Tablet, Film Coated
Product Images NDC 76385-112

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 76385-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (12.5 mg container)

Carvedilol 12.5 mg film-coated tablets label showing 100 tablets per bottle. The label states the product is Rx only and includes manufacturer Beximco Pharmaceuticals Ltd., and distributor Bayshore Pharmaceuticals LLC. It also features storage instructions and dosing notes.*

FDA Label Image

Principal Display Panel (25 mg container)

Carvedilol 25 mg film-coated tablets packaging label displays the product name, strength, dosage form, and quantity of 100 tablets. The label includes manufacturer Beximco Pharmaceuticals Ltd., distributor Bayshore Pharmaceuticals LLC, and storage instructions. It shows the NDC code 76385-113-01, with the indication for prescription use only.*

FDA Label Image

Principal Display Panel (3.125 mg container)

Carvedilol 3.125 mg film-coated tablets USP label. The label includes prescribing information, storage instructions, and dispensing guidelines. It states the product is Rx only, with 100 tablets per container. Manufactured by Beximco Pharmaceuticals Ltd and distributed by Bayshore Pharmaceuticals LLC.*

FDA Label Image

Principal Display Panel (6.25 mg container)

Carvedilol 6.25 mg film-coated tablets label showing dosage strength, manufacturer Beximco Pharmaceuticals Ltd., distributor Bayshore Pharmaceuticals LLC, NDC 76385-111-01, and container size of 100 tablets. The label includes storage and handling instructions, caution to keep out of reach of children, and prescription status indication (Rx only).*

FDA Label Image

Figure 1 (Figure 1)

A line graph comparing percentage mortality over time in months between placebo and Carvedilol groups. The graph shows lower mortality percentages for Carvedilol relative to placebo during the 21-month period, with a statistical significance P value of 0.0014 indicated.*

FDA Label Image

Figure 2 (Figure 2)

A horizontal forest plot showing hazard ratios for various patient subgroups including gender, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure, and spironolactone use, with a reference line at hazard ratio 1.0. Each subgroup is represented by a point estimate with confidence intervals, illustrating comparative risk assessments.*

FDA Label Image

Figure 3 (Figure 3)

A line graph comparing mortality percentage over 24 months between Carvedilol and Placebo groups. The graph shows two lines, one labeled Carvedilol and the other Placebo, with Placebo consistently higher in mortality percentage. The x-axis represents time in months, and the y-axis shows mortality percentage, with a statistical p-value of 0.03 indicated on the plot.*

FDA Label Image

Figure 4 (Figure 4)

A forest plot chart depicting hazard ratios with confidence intervals for different patient subgroups. The subgroups include age, gender, timing of randomization post myocardial infarction, prior use of intravenous beta blockers, Killip classification, use of thrombolytic therapy, status of percutaneous transluminal coronary angioplasty for myocardial infarction, history of congestive heart failure, diuretic use during myocardial infarction, presence of angina, hypertension, diabetes, heart rate, systolic blood pressure, and overall patient population. Each subgroup is represented by a point estimate and horizontal confidence interval bars along a hazard ratio scale from 0.4 to 1.3.*

FDA Label Image

Structural Formula (Structure)

Chemical structure diagram of carvedilol, depicting its molecular formula with aromatic rings, an alcohol group, and ether linkages, representing the active ingredient carvedilol used in oral tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.